Full Press Release Details
Corporation Reports First Quarter 2021 Financial Results and Provides Business Update
on Immuno-Oncology and
Vaccines is Supported with a Strong Balance Sheet
Call Begins at 10:00 a.m. Eastern Time Today
N.J. (May 14, 2021) - Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug
development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the
three months ended March 31, 2021, and provided an update on clinical development programs with GEN-1,
a DNA-based interleukin-12 (IL-12) immunotherapy in Phase I/II clinical development
for the localized treatment of ovarian cancer, and ThermoDox ,
a proprietary heat-activated liposomal encapsulation of doxorubicin under investigator-sponsored development for several cancer indications.
In addition, Celsion has two feasibility-stage platform technologies for the development
of novel nucleic acid-based immunotherapies and next-generation vaccines for infectious diseases.
entered 2021 with a focus on a novel DNA-based immunotherapy for ovarian cancer and an initiative for next-generation vaccines with
the potential to immunize against a broad range of infectious agents, including coronaviruses. Our platform technologies, TheraPlas
and PlaCCine, are rich with promise for a pipeline of product candidates that have potential to address difficult and unaddressed
diseases. During the first quarter, the Company extended its cash operating runway through 2024 and strengthened our balance sheet
with the successful execution of its financing strategy by raising more than $58 million in gross proceeds from two well placed,
registered direct offerings, sales under our at-the-market (ATM) equity facility, warrant exercises and the sale of our New Jersey
State NOLs," said Michael H. Tardugno, Celsion's chairman, president and chief executive officer.
Phase I/II OVATION 2 Study is more than 40% enrolled. With 23 clinical sites activated, encouraging trial data to date and the strong
commitment of our clinical investigators, we hope to complete enrollment before the end of 2021. Initial data at the 100 mg/m² dose
cohort appear to be consistent with the directionally impressive results reported from our Phase Ib dose-escalating OVATION I Study in
ovarian cancer. In the OVATION 2 study of 28 patients who completed interval debulking surgery, 81% of those treated with GEN-1 had an
R0 resection, compared with 58% of control patients, a 41% improvement."
Tardugno added, "During the first quarter of 2021, we announced an initiative to focus our considerable
DNA plasmid experience and competencies on DNA vaccine development, an approach we believe may represent an advance in nucleic acid immunotherapy.
Leveraging our clinical-stage TheraPlas platform, we envision a vaccine characterized by a single-plasmid DNA with multiple coding
regions. Celsion's plasmid vectors currently in development are designed to promote multiple antigens that are expressed by a single
pathogen in combination with a potent immune modifier such as IL-12. IL-12 is the active ingredient in our GEN-1 product candidate.
We are well positioned with a capital structure sufficient to support our planned R&D and clinical programs through transformative
milestones. In doing so, we look to create significant value for our shareholders, patients and the medical community."
Encouraging Interim Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer.
In February 2021, the Company provided an update on its Phase I/II OVATION 2 Study with GEN-1 in patients with advanced ovarian cancer.
The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV
ovarian cancer. NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy.
Following NACT, patients undergo interval debulking surgery, followed by three adjuvant cycles of chemotherapy and up to nine additional
weekly GEN-1 treatments, the goal of which is to delay disease progression and improve overall survival. To date, the Company has enrolled
more than 40% of the anticipated 110 patients to be enrolled into the OVATION 2 Study. Currently, 28 patients have had their interval
debulking surgery with the following results:
| 13 of 16 patients, or 81%, treated with GEN-1 had a R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed; | ||
| Seven of 12 patients, or 58%, in the control arm had an R0 resection; and, | ||
| These interim data represent a 41% improvement in R0 resection rates for GEN-1 patients compared with control arm patients and is consistent with the reported improvement in resection scores noted in the encouraging Phase I OVATION 1 Study, the manuscript of which has been submitted for peer-review publication. |
FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer. In February 2021, the Company announced receipt of Fast Track
designation from the U.S. Food and Drug Administration (FDA) for GEN-1. Fast Track designation is intended to facilitate the development
and expedite the regulatory review of drugs to treat serious conditions and fill an unmet medical need. According to the FDA, a Fast-Track
Drug must show some advantage over available therapy, including:
| Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomes | ||
| Avoiding serious side effects of an available therapy | ||
| Decreasing a clinically significant toxicity of an available therapy that is common and causes discontinuation of treatment |
Provisional U.S. Patent Application for a Broad Range of Next-Generation DNA Vaccines. In January 2021, the Company announced
the filing of a provisional U.S. patent application for a novel DNA-based, investigational vaccine for preventing or treating infections
from a broad range of infectious agents, including coronaviruses, using its PLACCINE DNA vaccine technology platform. The provisional
patent covers a family of novel composition of multi-cistronic vectors and polymeric nanoparticles that comprise the PLACCINE DNA vaccine
platform technology for preventing or treating infectious agents that have the potential for global pandemics, including the SARS-CoV-2
virus and its variants, using the Company's technology platform. Celsion's vaccine approach is designed to optimize the quality
of the immune response dictating the efficiency of pathogen clearance and patient recovery. Celsion has taken a multivalent approach
in an effort to generate an even more robust immune response that not only results in a strong neutralizing antibody response, but also
a more robust and durable T-cell response. Delivered with Celsion's synthetic polymeric system, the proprietary DNA plasmid is
protected from degradation and its cellular uptake is facilitated.
is a natural extension of the Company's synthetic, non-viral TheraPlas delivery technology currently in a Phase II trial for the
treatment of late-stage ovarian cancer with GEN-1. Celsion's proprietary multifunctional
DNA vaccine technology concept is built on the flexible PLACCINE technology platform that is amenable to rapidly responding to the SARS-CoV-2
virus, as well as possible future mutations of SARS-CoV-2, other future pandemics, emerging bioterrorism threats and novel infectious
diseases. Celsion's extensive experience with TheraPlas suggests that the PLACCINE-based nanoparticles are stable at storage temperatures
of 4oC to 25oC, making
vaccines developed on this platform suitable for broad worldwide distribution.
Vaccine Advisory Board. In February 2021, the Company announced the
formation of a Vaccine Advisory Board and the appointment of its first two members:
| Britt A. Glaunsinger, Ph.D., Professor, Virology & Molecular Biology, Howard Hughes Medical Institute, University of California, Berkeley; and | ||
| Xinzhen Yang, M.D., Ph.D., Independent Professional Consultant for the Gerson Lehman Group and former Director of Viral Vaccines / Program Lead of the HCMV Vaccine Program at Pfizer Inc. |
Balance Sheet Through Two Registered Direct Offerings of Common Shares Totaling $50 Million in Gross Proceeds.
| On January 26, 2021, the Company announced the closing of a registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules, resulting in net proceeds of $32.6 million after deducting placement agents' fees but before expenses payable by the Company. | ||
| On April 5, 2021, the Company announced the closing of a registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million , after deducting placement agents' fees but before expenses payable by the Company. |
intends to use the net proceeds for general corporate purposes, including research and development activities, capital expenditures and
$2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, with an Additional $5.0 Million
Expected in 2021-2023. In February 2021, the Company received approval from the New Jersey
Economic Development Authority's (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell $2.0 million
of its unused New Jersey net operating losses (NOLs)
for the tax years 2018 and 2019. The NOLs are typically sold at a small, single-digit discount to qualified companies with operations
in New Jersey. As a result, the Company was able to transfer this credit and receive approximately
$1.85 million of net cash proceeds in May 2021. An additional $5.0 million allocation of
NOL sales will be available to the Company during 2021-2023.
in Two Investor Events. In March 2021, the Company held
one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference. A webcast of Celsion's presentation
was pre-recorded and is available on the Company's website. In April 2021, Company management participated
in Alliance Global Partners' (AGP) Virtual Series. Michael H. Tardugno and Dr. Kursheed
Anwar were interviewed in a "Fireside Chat" by Matt Cross, Senior Biotech
Research Analyst at AGP. The discussion focused on the Company's lead product, GEN-1and on
its PLACCINE vaccine development platform. Requests to listen to a replay can be made by emailing agpevents@allianceg.com.
Results for the Three Months Ended March 31, 2021
reported a net loss for the first quarter of 2021 of $5.7 million ($0.09 per share) compared with a net loss of $5.1 million ($0.20 per
share) for the year-ago quarter. Operating expenses were $5.5 million for the first quarter of 2021, which represented a $0.6 million
or 13% increase from $4.9 million for the first quarter of 2020.
and development expenses were $2.6 million for the first quarter of 2021, a decrease of $0.5 million or 16% from $3.1 million for the
comparable period in 2020. Clinical development costs for the Phase III OPTIMA Study decreased to $0.1 million for the first quarter
of 2021, compared with $0.7 million for the prior-year quarter. In July 2020, the Company unblinded the OPTIMA Study and at the recommendation
of the Data Monitoring Committee halted the study due to futility. R&D costs associated with development of GEN-1 to support the
OVATION 2 Study as well as development of the PLACCINE DNA vaccine technology platform increased to $1.0 million for the first quarter
of 2021, compared with $0.9 million for the same period of 2020. Other costs related to the Company's clinical development programs
decreased by $0.2 million for the first quarter of 2021 compared with 2020, due to lower regulatory and manufacturing costs for the ThermoDox
development program.
and administrative expenses were $2.9 million for the first quarter of 2021, compared with $1.8 million for the first quarter of 2020.
This increase is primarily attributable to higher non-cash stock compensation expense of $0.8 million, an increase in professional fees
of $0.2 million and an increase in premiums for directors' and officers' insurance.
Company had $54.6 million in cash and cash equivalents, short-term investments and a receivable on the sale of NOLs as of March 31, 2021.
Combined with $15 million of gross proceeds received from the sale of equity in a registered direct offering that closed on April 5,